Skip to main content

Table 1 Patient characteristics

From: Interfractional target changes in brain metastases during 13-fraction stereotactic radiotherapy

Age Median, 70 years (range 42–85 years)
Sex (male/female) 19/4
Karnofsky Performance Status Median, 90 (range 50–100)
Primary tumor (number of brain metastases)
 Lung cancer 15 (19)
 Renal cell carcinoma 3 (3)
 Others 5 (5)
Prior whole-brain radiotherapy 2 cases (25 Gy/10 fr., 30 Gy/10 fr.)
Cystic component or necrosis (yes/no) 19/8
Treatment device per lesion
 TrueBeamSTx/Vero4DRT 25/2
Prescribed dose
 Prescribed to isocenter 4 lesions with 48.75 Gy/13 fr. (PTV was almost covered by 80% isodose line of the prescribed dose)
 D99.5% = 100% 23 lesions with 39–42 Gy/13 fr. (Dmax: almost 125% of the prescribed dose)
  1. PTV planning target volume, Dmax maximum dose